Chronic heart failure (CHF) describes the long-term management of heart failure outside the hospital setting. CHF patients are subject to high rates of mortality and morbidity. Frequent readmissions to the hospital mean that CHF is also a significant healthcare burden. Based on our survey results, here we discuss the similarities and differences between U.S. cardiologists' and primary care physicians' current treatment of CHF and what drives their choice of pharmacotherapy. We provide insight into how pharmacotherapy differs between heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) and how it changes with disease progression. We also discuss recent and anticipated changes in the use of the primary CHF agents, including Entresto, and the main drivers behind these changes.
- Which drugs are most commonly used to treat CHF, and how does treatment change with disease progression?
- Do treatment approaches differ between heart failure with preserved and reduced ejection fraction?
- What are the cardiologist-reported factors determining current prescribing patterns for CHF and recent/anticipated changes?
- What factors drive and constrain the prescribing of Entresto?
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that clients can create specific messaging around these treatment dynamics in order to more effectively increase or defend their market position.
Markets covered: United States
Methodology: Survey of 52 cardiologists and 50 primary care physicians in the United States, completed in February 2018.
Indication coverage: CHF
Key drugs covered: Entresto, Corlanor, beta blockers, ACE inhibitors, ARBs, diuretics, nitrates, spironolactone, eplerenone
- Heart Failure - Current Treatment - Detailed, Expanded Analysis: Chronic Heart Failure: Physician Insights (US)
Author(s): Dominika Rudnicka-Noulin, PhD, MSc
Dominika Rudnicka-Noulin, PhD, MSc is a senior business insights analyst in the Cardiovascular, Metabolic and Renal division at Decision Resources Group, specializing in cardiovascular diseases, with expertise in heart failure and acute coronary syndrome.
Prior to joining DRG, Dominika held a position of an associate editor at Nature Communications, working across a variety of therapy areas. Dominika also worked for three years as a Postdoctoral Research Associate on a joint project between Imperial College London and MedImmune aimed at developing more potent antibody-based drugs. Dominika gained her PhD at the Institut Pasteur in Paris, France where her work was funded by the European Commission Marie Skłodowska-Curie Actions